Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

PURPOSE: Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Shulman, Lawrence N., Berry, Donald A., Cirrincione, Constance T., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Shapiro, Charles L., Schneider, Charles J., Kimmick, Gretchen, Burstein, Harold J., Norton, Larry, Muss, Hyman, Hudis, Clifford A., Winer, Eric P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2014
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105484/
https://ncbi.nlm.nih.gov/pubmed/24934787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.53.7142
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge